Pramlintide
Pramlintide (Symlin) is a synthetic analog of amylin, FDA-approved as an adjunct to insulin therapy in type 1 and type 2 diabetes. It helps control post-meal blood sugar spikes and promotes modest weight loss.
Mechanism of Action
Mimics amylin's effects: slows gastric emptying, suppresses glucagon secretion after meals, and promotes satiety through central mechanisms. Complements insulin therapy.
Dosage Overview
Dose Range
15 mcg – 120 mcg
Route
subcutaneous
Frequency
3x daily
Cycle Length
12–52 weeks
Reconstitution
Typical Dosage (Research)
Type 1: Start 15mcg before meals, titrate to 30-60mcg. Type 2: Start 60mcg, may increase to 120mcg. Always with meal containing 30+ grams carbs or 250+ calories.
Subcutaneous injection immediately before major meals. Must reduce mealtime insulin by 50% when starting to prevent hypoglycemia. Never mix with insulin.
Considerations for Men & Women
Women: Amylin analog used alongside insulin for diabetes management. No sex-specific dose adjustments. Pregnancy category C — use only if benefit outweighs risk. May cause nausea more frequently in initial use.
Men: Same dosing and safety profile. Used to reduce postprandial glucose spikes. Hypoglycemia risk when combined with insulin applies equally to both sexes.
Individual responses vary. These notes reflect general trends from research literature and are not medical advice.
Quick Calculator
Quick Calculator
Concentration: 2,500 mcg/ml
Volume to inject: 0.01 ml
Syringe units (U-100): 0.6 units
Pre-filled with Pramlintide defaults. Adjust values as needed.
Side Effects & Risks
Nausea (very common initially), headache, anorexia, vomiting, and abdominal pain. GI effects typically improve over time.
Severe hypoglycemia risk, especially in type 1 diabetes. Boxed warning about insulin-induced severe hypoglycemia. Requires careful dose management.
Who Uses Pramlintide
Diabetics on insulin seeking better post-meal control, those not achieving goals with insulin alone, patients wanting modest weight loss support.
Similar Peptides
View All Alternatives →Setmelanotide (Imcivree) is an FDA-approved MC4R agonist for chronic weight management in patients with obesity due to specific genetic conditions (POMC, PCSK1, or LEPR deficiency).
Mod GRF 1-29 (Modified GRF 1-29, also called CJC-1295 without DAC or Tetrasubstituted GRF 1-29) is a modified growth hormone-releasing hormone analog with improved stability over natural GHRH.
Dulaglutide (Trulicity) is a once-weekly GLP-1 receptor agonist for type 2 diabetes. Its larger molecular size from fusion with an Fc fragment extends half-life and may reduce some GI side effects.
Cagrilintide is a long-acting amylin analog in development, showing promising results when combined with semaglutide (CagriSema). Amylin is a hormone co-secreted with insulin that promotes satiety.
Semaglutide is a GLP-1 receptor agonist that has revolutionized weight management and diabetes treatment. FDA-approved as Ozempic (diabetes), Wegovy (weight loss), and Rybelsus (oral form), it has become one of the most prescribed peptides worldwide.